What happened with DNA today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Most of Ginkgo Bioworks’ revenue comes from cell engineering, with customer R&D programs as the main driver. Customers pay it to develop engineered cells, strains or enzymes that meet agreed specifications; they—not Ginkgo—manufacture and sell the resulting end products. Its Autonomous Lab combines automated laboratory work, software and reusable biological data. Ginkgo generally charges fixed fees for defined research work and also sells data-generation services through Datapoints and laboratory automation systems called Reconfigurable Automation Carts, with ongoing support.
Its smaller biosecurity business serves mainly governments. Through Canopy and partnerships including the CDC and XpresCheck, it collects samples, arranges laboratory testing and sequencing, and provides analysis to monitor pathogens. Customers pay for those services, and demand depends heavily on government and other public-health funding.
A limited number of large customers supply a significant share of revenue. Cell-engineering work depends on their research budgets and willingness to outsource; multi-year collaborations generally do not guarantee minimum annual demand. Some legacy agreements also give Ginkgo royalties, milestone payments or equity tied to customer product success, although royalties are not a material revenue source. Those returns depend on customers advancing and commercializing products. Engineered biological products face country-specific regulatory requirements, while testing services require appropriate laboratory certifications and licenses.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Ginkgo’s results hinge on commercial and government biological R&D budgets and surveillance funding; WuXi Biologics is another rival to watch in therapeutics research services.
Ginkgo relies on custom synthetic DNA supplied by Twist Bioscience Corporation for its paid cell-engineering projects, with minimum spending committed under a multiyear agreement. Watch DNA pricing and delivery: shortages or higher costs can delay Ginkgo’s customer work, while its remaining minimum payments are non-refundable credits for future purchases.
Codexis, Inc. competes with Ginkgo for customers paying to develop enzymes that improve biological processes. Its work supplying enzymes for pharmaceutical manufacturing and developing RNA-drug production processes is the concrete overlap to watch, rather than its business as a whole.
Evotec SE competes with Ginkgo for pharmaceutical and biotechnology customers paying for outsourced biological research and data generation. Watch Evotec’s Discovery & Preclinical Development service business, where customer spending on drug discovery is more relevant to Ginkgo than Evotec’s biologics manufacturing revenue.
AbCellera Biologics Inc. competes with Ginkgo for pharmaceutical partners paying for antibody discovery and engineering, with potential payments later as resulting drugs advance. Watch its partner-initiated discovery programs for the research overlap; royalties from marketed drugs reflect a later stage than Ginkgo’s service fees, which do not depend on customer commercialization.
Thermo Fisher Scientific supplies instruments and consumables for Ginkgo’s Autonomous Lab while also competing to sell laboratory automation to research customers. Its equipment pricing and availability matter to Ginkgo’s project delivery, while its automation offerings compete with the RAC systems Ginkgo sells to outside laboratories.
Charles River Laboratories competes with Ginkgo for outsourced research and data-generation spending, especially from pharmaceutical customers discovering drugs. Watch its Discovery and Safety Assessment business rather than total revenue: pharmaceutical and biotechnology customers accounted for 35% of Ginkgo’s Cell Engineering revenue in 2025.
Recursion Pharmaceuticals, Inc. and Ginkgo both use automated laboratory experiments and computational models to make biological discoveries and build research programs for pharmaceutical partners. Watch Recursion’s partner programs rather than only its own drug pipeline: those programs are closer to the research and data services Ginkgo sells to customers.
XWELL, Inc.’s XpresTest works with Ginkgo’s Concentric on CDC-funded airport pathogen surveillance, so funding and contract extensions matter to both businesses. Watch XpresTest’s U.S. international-airport surveillance contracts—not XWELL’s traveler spa sales—for a read on funding relevant to Ginkgo’s Biosecurity services.
Thermo Fisher Scientific, Inc. earningsTMO
Thermo Fisher’s report can show whether instrument and consumables supply and pricing support Ginkgo’s lab work, and how strongly its automation competes with Ginkgo’s RAC systems.
Look for supply and pricing signals in Thermo Fisher’s instruments and consumables business, alongside sales of its lab automation. Reliable supply and manageable prices help Ginkgo deliver projects on time and control costs; disruption or higher costs strain delivery, while stronger automation sales mean tougher competition for RAC systems.
Fed Interest Rate Decision
For Ginkgo, the Fed’s policy rate shapes interest earned on its cash and short-term investments and the cost of borrowing to fund its research and services.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates may increase interest income on Ginkgo’s cash and short-term investments, but make any new borrowing to fund its operations more expensive.
If it comes in below expectations
Lower rates may reduce interest income on Ginkgo’s cash and short-term investments, but make any new borrowing to fund its operations less expensive.
Charles River Laboratories International, Inc. earningsCRL
Charles River’s Discovery and Safety Assessment business will show whether drug companies are spending on outsourced research, where Ginkgo also sells Cell Engineering programs.
Focus on demand in Charles River’s Discovery and Safety Assessment business, not just its total revenue. Resilience would show drug companies still pay for outsourced research, supporting demand for Ginkgo’s Cell Engineering programs; weakness would suggest tighter customer budgets and harder competition for projects.
Recursion Pharmaceuticals, Inc. earningsRXRX
Recursion’s partner programs can show whether drug companies are still paying for automated biological experiments and data generation, overlapping with Ginkgo’s research services.
Watch whether Recursion’s partner programs continue and whether pharmaceutical partners keep investing. More or faster-moving programs would show customers still pay for automated experiments and data, supporting demand for Ginkgo’s related services; fewer or stalled programs would point to weaker research budgets.
Ginkgo Bioworks Holdings, Inc. earningsThis company
Ginkgo Bioworks charges for cell-engineering projects and biosecurity services, and this report will show whether customer work is sustaining revenue and narrowing segment losses.
Read Cell Engineering and Biosecurity revenue alongside each segment’s operating loss. Steady revenue with narrower losses would show customer programs and services covering more of their delivery costs; falling revenue with losses still wide would show that paid demand or cost control has not yet closed the gap.
Twist Bioscience Corporation earningsTWST
Twist supplies synthetic DNA for Ginkgo’s Cell Engineering projects, and its report can show whether supply or pricing could delay customer work or raise costs.
Watch Twist’s DNA supply and pricing. Reliable supply at manageable prices helps Ginkgo complete customer projects on time and use its committed payments toward future purchases; shortages or higher prices can delay work, squeeze costs, and make those purchase commitments harder to use fully.
XWELL, Inc. earningsXWEL
XWELL’s XpresTest works with Ginkgo’s Concentric on airport pathogen surveillance, and its report can show whether funding and contracts for that shared work continue.
Watch whether XWELL’s U.S. international-airport surveillance contracts continue and remain funded; its traveler spa business is not the signal. Continuity would mean this partnership still supports Biosecurity work, while reduced funding or lost contracts would weaken this source of government-linked service demand for Ginkgo.
